Black Diamond Therapeutics (BDTX) Projected to Announce Earnings on Thursday

Key Points

• Black Diamond Therapeutics is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast a loss of $0.055 per share and revenue of approximately $8.33 million; the earnings call is scheduled for 4:00 p.m. ET.
• The company previously reported a Q2 loss of $0.17 per share, beating the consensus estimate of a $0.20 loss. Analysts expect losses of $0.57 per share for the current fiscal year and $1.03 per share next year.
• Analyst sentiment is moderately positive, with seven Buy, two Hold and one Sell rating, and an average price target of $11 versus the stock’s recent price of $1.83. Shares have a market capitalization of about $105 million and have traded between $1.60 and $4.94 over the past year.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Black Diamond Therapeutics to announce earnings of ($0.0550) per share and revenue of $8.33 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. On average, analysts expect Black Diamond Therapeutics to post ($0.57) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.

Black Diamond Therapeutics Stock Up 4.6%

Black Diamond Therapeutics stock opened at $1.83 on Thursday. Black Diamond Therapeutics has a 12 month low of $1.60 and a 12 month high of $4.94. The stock has a market cap of $105.13 million, a P/E ratio of -2.44 and a beta of 3.32. The company's fifty day simple moving average is $1.96 and its 200-day simple moving average is $2.20.

Wall Street Analysts Forecast Growth

BDTX has been the subject of a number of research reports. Jefferies Financial Group reissued a "buy" rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. TD Cowen restated a "buy" rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Wall Street Zen raised Black Diamond Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 24th. Raymond James Financial reaffirmed an "outperform" rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Black Diamond Therapeutics in a research note on Friday, October 9th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.00.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.

Black Diamond's pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.